B. Munárriz

发表

Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks

J. M. Jerez, A. Lluch, A. Llombart-Cussac, 2005, Breast Cancer Research and Treatment.

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

Mark T. W. Ebbert, Charles M Perou, Roy R. L. Bastien, 2012, BMC Medical Genomics.

Predicting response and survival in chemotherapy-treated triple-negative breast cancer

E Mardis, E. Mardis, C. Fan, 2014, British Journal of Cancer.

[Epidemiological study of the GEICAM group about breast cancer in Spain (1990-1993): El Alamo project].

A. Lluch, A. Llombart-Cussac, E. Alba, 2004, Medicina clinica.

Spanish Breast Cancer Research Group (GEICAM) population-based study on breast cancer outcomes: El Alamo project (1990-1997)

A. Lluch, E. Alba, B. Munárriz, 2005 .

Synchronous and metachronous bilateral breast cancer: a long-term single-institution experience

B. Munárriz, A. Santaballa, L. Palomar, 2012, Medical Oncology.

Adjuvant docetaxel for high-risk, node-negative breast cancer.

A. Ruíz, A. Lluch, J. Zaluski, 2010, The New England journal of medicine.

Randomised comparison of ceftazidime and imipenem as initial monotherapy for febrile episodes in neutropenic cancer patients.

J. Aparicio, B. Munárriz, C. Herranz, 1996, European Journal of Cancer.

The «El Álamo» project (1990–1997): two consecutive hospital-based studies of breast cancer outcomes in Spain

A. Ruíz, A. Lluch, A. Llombart-Cussac, 2006, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Time-to-progression in breast cancer: a stratification model for clinical trials.

A. Lluch, E. Alba, B. Munárriz, 2008, Breast.

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

Arrate Plazaola, Emilio Alba, Carmen Crespo, 2008, Journal of the National Cancer Institute.

PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

Donald A. Berry, Mark T. W. Ebbert, Charles M. Perou, 2013, Breast Cancer Research and Treatment.

Hepatic resection in breast cancer metastases: should it be considered standard treatment?

B. Munárriz, A. Santaballa, V. Calderero, 2004, Breast.

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.

A. Carrato, J. Albanell, B. Munárriz, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term follow-up and prognostic factors in Ewing's sarcoma. A multivariate analysis of 116 patients from a single institution.

J. Aparicio, B. Munárriz, C. Herranz, 1998, Oncology.

Long-Term Follow-Up and Prognostic Factors in Ewing’s Sarcoma

J. Aparicio, B. Munárriz, C. Herranz, 1997, Oncology.

Small cell lung cancer in the elderly: factors influencing treatment decision and effect on survival

J. Aparicio, B. Munárriz, C. Herranz, 2000, Revista de Oncología.

Long-term results after combined modality treatment for non-metastatic osteosarcoma

J. Aparicio, B. Munárriz, A. Oltra, 1999, Medical oncology.

Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients.

J. Aparicio, B. Munárriz, C. Herranz, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial

K. Weber, A. Ruíz, E. Alba, 2014, Breast Cancer Research.

Specific oncological contribution of cathepsin D and pS2 in human breast cancer: their relationship with TNM status, estradiol receptors, epidermal growth factor receptor and neu amplification.

V. Guillem, J. A. Lopez, B. Munárriz, 1996, Clinica chimica acta; international journal of clinical chemistry.

Cost‐Benefit Analysis of a Follow‐up Program in Patients with Breast Cancer: A Randomized Prospective Study

B. Munárriz, A. Oltra, A. Santaballa, 2007, The breast journal.

Validation of the 2001 St Gallen risk categories for node-negative breast cancer using a database from the Spanish Breast Cancer Research Group (GEICAM).

A. Lluch, A. Llombart-Cussac, E. Alba, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of Timing of Initiation of Adjuvant Chemotherapy Over Survival in Breast Cancer: A Negative Outcome Study by the Spanish Breast Cancer Research Group (GEICAM)

A. Ruíz, J. Schneider, E. Alba, 2006, Breast Cancer Research and Treatment.

Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status.

A. Ruíz, A. Lluch, V. Guillem, 1997, Clinica chimica acta; international journal of clinical chemistry.

Multicenter, randomized phase III study of adjuvant chemotherapy for axillary positive breast cancer (APBC) comparing 6 cycles (cy) of FEC vs 4 cy of FEC followed by 8 weekly paclitaxel (T) administrations: Safety analysis of GEICAM 9906 trial.

A. Ruíz, E. Alba, B. Munárriz, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.

J. Mayordomo, A. Ruíz, A. Lluch, 2008, Journal of the National Cancer Institute.